Chai Discovery Secures $130M Series B Led by Oak HC/FT and General Catalyst

Why It Matters

The capital infusion positions Chai Discovery to scale its AI‑driven drug discovery tools, potentially shortening development timelines for pharma companies. Its billion‑dollar valuation underscores growing investor confidence in biotech AI solutions.

Key Takeaways

• $130M Series B led by Oak HC/FT, General Catalyst.
• Valuation reaches $1.3B post‑round.
• Investors include OpenAI, Thrive Capital, Menlo Ventures.
• AI predicts and reprograms biochemical molecule interactions.
• Funding fuels platform scaling and pharma partnerships.

Pulse Analysis

Artificial intelligence is reshaping biotech by enabling rapid prediction of molecular behavior, a capability that can dramatically cut the cost and time of drug development. Chai Discovery leverages deep‑learning models to simulate how biochemical molecules interact, offering a virtual laboratory for researchers. This approach aligns with a broader industry shift toward computational drug design, where data‑rich AI platforms are becoming essential assets for pharmaceutical pipelines.

The recent $130 million Series B, co‑led by Oak HC/FT and General Catalyst, brings Chai Discovery’s valuation to $1.3 billion, signaling strong market endorsement. Participation from strategic investors such as OpenAI and Thrive Capital adds both capital and expertise, positioning the company at the nexus of AI innovation and life‑science financing. The diversified investor base reflects confidence that Chai’s technology can deliver tangible returns by accelerating candidate identification and reducing attrition rates in clinical trials.

Looking ahead, the funding will likely fuel expansion of Chai’s computational platform, recruitment of top scientific talent, and formation of deeper collaborations with pharmaceutical firms. As the AI‑driven drug discovery sector matures, firms that can demonstrate scalable, reproducible results will capture a larger share of partnership deals and licensing revenue. Chai Discovery’s next phase may set new benchmarks for speed and precision in molecule design, influencing how the industry approaches R&D investment and risk management.

Deal Summary

San Francisco‑based AI firm Chai Discovery announced a $130 million Series B financing round, co‑led by Oak HC/FT and General Catalyst. The round also included participation from Thrive Capital, OpenAI, Dimension, Menlo Ventures, Lachy Groom, Yosemite, Neo, SV Angel, Emerson Collective and Glade Brook, valuing the company at $1.3 billion.